Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

San Antonio, Texas 78245


Purpose:

To estimate the response rate, response duration, clinical benefit, and toxicity of mitoguazone dihydrochloride (MGBG) in patients with AIDS-related refractory or relapsing non-Hodgkin's lymphoma (NHL).


Study summary:

Patients receive infusions of MGBG on days 1 and 8 and every 2 weeks thereafter. It is suggested that a lumbar puncture be performed to evaluate for leptomeningeal disease.


Criteria:

Inclusion Criteria Patients must have: - HIV positivity by ELISA confirmed by Western blot. - AIDS-related NHL that is refractory or relapsed. - Life expectancy of at least 12 weeks. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: - Concomitant malignancy OTHER THAN curatively treated carcinoma in situ of the cervix; basal or squamous cell carcinoma of the skin; or non-active, non-visceral Kaposi's sarcoma not requiring active chemotherapy. - Active uncontrolled bacterial infection, viral infection (other than herpes simplex), or fungal infection (other than oropharyngeal candidiasis) that requires treatment within 2 weeks of study entry. - Significant cardiovascular disease. Concurrent Medication: Excluded: - Hormonal therapy (except medications given for muscle wasting, such as testosterone or Megace). - Other chemotherapy. - Investigational anti-cancer drugs. Concurrent Treatment: Excluded: - Concomitant radiation to sites other than CNS. Patients with the following prior conditions are excluded: Prior malignancy OTHER THAN curatively treated carcinoma in situ of the cervix; basal or squamous cell carcinoma of the skin; or non-active, non-visceral Kaposi's sarcoma not requiring active chemotherapy. Recommended: - Prophylaxis for PCP and oral candidiasis. Required in patients with leptomeningeal disease: - Intrathecal methotrexate or cytarabine (Ara-C). - Leucovorin. Required in patients with leptomeningeal disease: Cranial radiation to a helmet field.


NCT ID:

NCT00002348


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

San Antonio, Texas 78245
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 19, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.